Gary Herman

8.2k citations

58 papers · 2.6k indexed · h-index 27

Endocrinology, Diabetes and Metabolism top 0.5%
- Diabetes Treatment and Management 25
Oncology top 5%
- Peptidase Inhibition and Analysis 15
Pharmacology top 2%
Cellular and Molecular Neuroscience top 5%
- Neuropeptides and Animal Physiology 5
Surgery top 5%
- Pancreatic function and diabetes 10
Cell Biology
- Cellular transport and secretion 6
Epidemiology
- Neuroendocrine Tumor Research Advances 4
Infectious Diseases
- SARS-CoV-2 and COVID-19 Research 3
Immunology and Allergy
- Allergic Rhinitis and Sensitization 3

Co-authors: John A. Wagner Arthur Bergman Bingming Yi Keith Gottesdiener Karen Snyder Kenneth C. Lasseter Michael Tanen Wesley Tanaka
Cited by: Endocrinology, Diabetes and Metabolism Oncology Pharmacology
Journals: The Journal of Clinical Pharmacology (10 papers)Clinical Pharmacology & Therapeutics (5 papers)Journal of Allergy and Clinical Immunology (3 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Gary Herman

55 papers receiving 2.5k citations

Peers

Countries citing papers authored by Gary Herman

Since Specialization

Citations

This map shows the geographic impact of Gary Herman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Herman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Herman more than expected).

Fields of papers citing papers by Gary Herman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Herman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Herman. The network helps show where Gary Herman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gary Herman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gary Herman Line = papers co-authored together Gary Herman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial Nature Communications ·Dinko González Trotter,Stephen Donahue,Chris Wynne,Shazia Ali,Prodromos Parasoglou,Anita Boyapati,Kusha Mohammadi,Bret J. Musser,Stephanie Boggasch,Jason Mastaitis,Mark W. Sleeman,David J. Glass,Naoko Seto,Jorge Servián-López,Giulia Covezzi,Thiru Rajagopal,Robert Pordy,George D. Yancopoulos,Gary Herman	2025	2
2	Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy Allergy ·Matthew F. Wipperman,Kaitlyn Gayvert,Amanda Atanasio,Claire Q. Wang,Jonathan Corren,http://lattes.cnpq.br/0082635962322354,Ian Setliff,M. E. van Bolhuis,Elizabeth Laws,Anna Judenmann,Sivan Harel,Jennifer Maloney,Gary Herman,Jamie Orengo,Wei Keat Lim,Sara Hamon,Jennifer D. Hamilton,Meagan P. O’Brien	2024	12
3	Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection Open Forum Infectious Diseases ·Yuhang Jiang,Meagan P. O’Brien,Andrea T. Hooper,Eduardo Forleo‐Neto,Flonza Isa,Peijie Hou,Kuo‐Chen Chan,Myron S. Cohen,Mary Marovich,Jennifer D. Hamilton,Boaz Hirshberg,Gary Herman,Bret J. Musser	2023	1
4	Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial Open Forum Infectious Diseases ·Selin Somersan-Karakaya,Eleftherios Mylonakis,Markus B Heckmann,Ernesto Oviedo‐Orta,Meagan P. O’Brien,Veronica Mas Casullo,Adnan Mahmood,Andrea T. Hooper,Mohamed Hussein,Shazia Ali,Francisco M. Marty,Eduardo Forleo‐Neto,Rafia Bhore,Jennifer D. Hamilton,Gary Herman,Boaz Hirshberg,David M. Weinreich	2023	1
5	A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Open Forum Infectious Diseases ·Elizabeth R. Brown,Meagan P. O’Brien,TEKİN Burcu,Flonza Isa,Eduardo Forleo‐Neto,Kuo‐Chen Chan,Peijie Hou,Myron S. Cohen,Gary Herman,Ruanne V. Barnabas	2023	0
6	Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans Psychopharmacology ·Yong‐Yeon Cho,Paul Maruff,John T. Connell,AG. JABARA,Nicole Calder,Scott M. Doran,Sabrina Fox‐Bosetti,Digby Nicholas Blair Whyte,John J. Renger,Gary Herman,Christopher Lines,Ajay Verma	2011	31
7	Short‐term metabolic effects of prednisone administration in healthy subjects Diabetes Obesity and Metabolism ·Eunkyung Kauh,Lori Mixson,Sudha S. Shankar,Gebrie Getu Alemu,Bhumesh Tyagi,Linda Morrow,Lutz Heinemann,M. Ruddy,Gary Herman,David E. Kelley,Marcus Hompesch	2011	17
8	Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males British Journal of Clinical Pharmacology ·Gary Herman,Goutam C. Mistry,Bingming Yi,Arthur Bergman,Amy Q. Wang,Wei Zeng,Li Chen,Karen Snyder,Jon Ruckle,Patrick Larson,Michael J. Davies,Ronald B. Langdon,Keith Gottesdiener,John A. Wagner	2010	29
9	Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure Journal of the American Society of Hypertension ·N Neha,Irene Nunes,James A. Bolognese,Deborah L. Miller,Ihor Kudriavtsev,BETÜL EYUBOĞLU,William B. Smith,Gary Herman,Peter U. Feig	2010	6
10	Sitagliptin, an dipeptidyl peptidase‐4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects British Journal of Clinical Pharmacology ·Goutam C. Mistry,Arthur Bergman,Wei Zheng,David Hreniuk,Miguel A. Zinny,Keith Gottesdiener,John A. Wagner,Gary Herman,Marcella Ruddy	2008	42
11	Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Current Medical Research and Opinion ·M Hanefeld,Gary Herman,Mei Wu,Carolyn Mickel,لاوسین سلیمان,Peter P. Stein,(unknown)	2007	139
12	Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology ·Rajesh Krishna,Arthur Bergman,Patrick Larson,Josée Côté,Kenneth C. Lasseter,Cheryl Ferrell,Amy Wang,Wei Zeng,Li Chen,John A. Wagner,Gary Herman	2007	56
13	Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers Biopharmaceutics & Drug Disposition ·Arthur Bergman,Goutam C. Mistry,Wen‐Lin Luo,正則江藤,Julie A. Stone,Amy Wang,Wei Zeng,Li Chen,Stacy C. Dilzer,Kenneth C. Lasseter,Gary Herman,John A. Wagner,Rajesh Krishna	2007	14
14	Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin Clinical Pharmacology & Therapeutics ·Gary Herman,Peter P. Stein,Nancy A. Thornberry,John A. Wagner	2007	135
15	Human Pharmacokinetics and Interconversion of Enantiomers of MK‐0767, a Dual PPARα/γ Agonist The Journal of Clinical Pharmacology ·BakerThomas,草深竹志,Mipalinda Mipalinda,Howard Greenberg,Gary Herman,John A. Wagner	2007	7
16	Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes Current Medical Research and Opinion ·Gary Herman,Arthur Bergman,Bingming Yi,Mark Kipnes,(unknown)	2006	77
17	Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects The Journal of Clinical Pharmacology ·Gary Herman,Arthur Bergman,Fang Liu,Rinat Degani,Amy Q. Wang,Wei Zeng,Li Chen,Karen Snyder,Deborah Hilliard,Michael Tanen,Wesley Tanaka,Alan G. Meehan,Kenneth C. Lasseter,Stacy C. Dilzer,Robert A. Blum,John A. Wagner	2006	146
18	Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Clinical Pharmacology & Therapeutics ·Gary Herman,C. Melinda Stevens,Koen Vandyck,Arthur Bergman,Bingming Yi,М. Чегерев,Karen Snyder,D Hilliard,Michael Tanen,Wesley Tanaka	2005	414
19	Identification of Discrete Classes of Endosome-derived Small Vesicles as a Major Cellular Pool for Recycling Membrane Proteins Molecular Biology of the Cell ·S.S. Usmanova,Frank Bonzelius,Seng Hui Low,Holger Wille,Thomas Weimbs,Gary Herman	2001	54
20	Recycling of Synaptic Vesicle Membrane Components Cold Spring Harbor Symposia on Quantitative Biology ·Yudai Kaneda,Najla Mnif,Frank Bonzelius,Claire Desnos,Gary Herman,L Clift-O'Grady,R B Kelly	1995	2

About Gary Herman

Gary Herman is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology, Immunology and Allergy, Cell Biology and Surgery, having authored 58 papers that have together received 2.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (25 papers), Peptidase Inhibition and Analysis (15 papers), Pancreatic function and diabetes (10 papers), Cellular transport and secretion (6 papers), Neuropeptides and Animal Physiology (5 papers), Neuroendocrine Tumor Research Advances (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and Allergic Rhinitis and Sensitization (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.8k citations), Oncology (718 citations), Pharmacology (423 citations), Cellular and Molecular Neuroscience (384 citations) and Surgery (758 citations). Gary Herman has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include John A. Wagner, Arthur Bergman, Bingming Yi, Keith Gottesdiener, Karen Snyder, Kenneth C. Lasseter, Michael Tanen, Wesley Tanaka, Peter P. Stein and Michael J. Davies. Their work appears in journals such as The Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, Journal of Allergy and Clinical Immunology, Current Medical Research and Opinion and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact